Format

Send to

Choose Destination
Eur Urol Focus. 2018 Dec;4(6):825-833. doi: 10.1016/j.euf.2017.02.018. Epub 2017 Mar 9.

Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.

Author information

1
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
2
Exiqon A/S, Vedbaek, Denmark.
3
Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark.
4
Department of Urology, Aarhus University Hospital, Aarhus, Denmark.
5
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. Electronic address: kdso@clin.au.dk.

Abstract

BACKGROUND:

Widespread use of prostate-specific antigen (PSA) testing for prostate cancer (PC) detection has led to extensive overdiagnosis and overtreatment. Urine-based microRNA (miRNA) biomarkers could be useful in PC diagnosis and prognosis.

OBJECTIVE:

To train and validate urine-based microRNA (miRNA) biomarkers that may assist in PC diagnosis and prognosis.

DESIGN, SETTING, AND PARTICIPANTS:

We profiled the expression levels of 92 miRNAs via reverse transcriptase-poymerase chain reaction in cell-free urine samples from 29 patients with benign prostatic hyperplasia (BPH) and 215 patients with clinically localized PC (cohort 1). Our findings were validated in an independent cohort of 29 BPH patients and 220 patients with clinically localized PC (cohort 2).

RESULTS AND LIMITATIONS:

We identified and validated several deregulated miRNAs in urine samples from PC patients. In addition, we trained a novel diagnostic three-miRNA model (miR-222-3p*miR-24-3p/miR-30c-5p) that distinguished BPH and PC patients with an area under the curve (AUC) of 0.95 in cohort 1, and was successfully validated in cohort 2 (AUC 0.89). Furthermore, we trained a novel prognostic three-miRNA model (miR-125b-5p*let-7a-5p/miR-151-5p) that predicted time to biochemical recurrence after radical prostatectomy independently of routine clinicopathological parameters in cohort 1, and was successfully validated in cohort 2.

CONCLUSIONS:

Future clinical implementation of our novel diagnostic and prognostic three-miRNA signatures could help in primary diagnosis of PC and guide treatment decisions. Further validation studies are warranted.

PATIENT SUMMARY:

Using two large patient cohorts, we searched for novel prostate cancer biomarkers in urine. We found two new sets of microRNA biomarkers in urine that could accurately predict the presence of prostate cancer and the likelihood of recurrence after prostatectomy. Further studies are needed before an actual clinical test can be developed.

KEYWORDS:

Biomarker; Diagnosis; MicroRNA; Prognosis; Prostate cancer; Urine

PMID:
28753866
DOI:
10.1016/j.euf.2017.02.018
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center